Berkshire-based Occuity has received funding for its non-contact, optical glucose meter.

The device is designed to enable the 4.7 million people living in the UK with diabetes to monitor their blood-sugar levels through an eye scan.

The medical technology start-up received a £2.85 million investment for development of the device, which is called Occuity Indigo.

The team, comprised of experts in optics, mechanical engineering, and industrial design, are also collaborating with the medical and academic world including partnerships with the Royal Berkshire Hospital and the University of Bristol.

“We’re delighted to have become the largest ever MedTech raise on Seedrs with over 850 investors from 37 countries, sharing our vision,” said chief executive and co-founder of Occuity, Dr. Dan Daly. “Diabetes is a growing, global problem and we believe our technology will enable health services throughout the world to monitor and screen for diabetes, improving the clinical outcomes for the hundreds of millions of people who are unaware they have pre-diabetes or diabetes.

“The Occuity Indigo will then make regular glucose testing easier, faster and pain-free, improving the daily lives of many millions more people worldwide.”

Share Story: